Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
BioAtla Community
NasdaqGM:BCAB Community
1
Narratives
written by author
0
Comments
on narratives written by author
7
Fair Values set
on narratives written by author
Create a narrative
BioAtla
Popular
Undervalued
Overvalued
Community Investing Ideas
BioAtla
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Mec-V And ROR2-ADC Programs Will Achieve Clinical Milestones
Key Takeaways Promising results in clinical programs and strategic partnerships indicate potential for increased revenue, improved net margins, and financial stability through collaboration income. Resource realignment and reduced R&D expenses suggest better operational efficiency and net margin improvement over the next year.
View narrative
US$8.33
FV
94.8% undervalued
intrinsic discount
12.35%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
2 days ago
author updated this narrative
Your Valuation for
BCAB
BCAB
BioAtla
Your Fair Value
US$
Current Price
US$0.43
75.4% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-119m
68m
2015
2018
2021
2024
2025
2027
2030
Revenue US$67.9m
Earnings US$13.5m
Advanced
Set Fair Value